Based in Sweden, Cereno Scientific is focused on the development of innovative, effective and safe treatments for people with rare cardiovascular and pulmonary diseases. Lead asset CS1, an HDAC inhibitor that acts as an epigenetic modulator, is currently being investigated in a Phase II clinical trial for the treatment of PAH.
Healthcare |
edison tv
Healthcare |
Flash
Healthcare |
Comment
Healthcare |
Flash
Eva Jagenheim
CFO
Jeppe Øvlesen
Chairman
Sten Sörensen
CEO
thematic
Consumer
thematic
Energy & Resources